Iatrogenic esophageal dysmotility as a barrier to transplantation in pulmonary arterial hypertension

Esophageal dysmotility is identified as a contraindication to lung transplantation at some centers due to increased risks of acute rejection, pulmonary infection, and chronic lung allograft dysfunction. Phosphodiesterase-type 5 inhibitors (PDE5i) are a cornerstone pharmacotherapy for pulmonary arter...

Full description

Bibliographic Details

Published in:	JHLT Open
Main Authors:	Michael S. Miller, Shelsey W. Johnson, Alexander R. Opotowsky, Michael J. Landzberg, Nirmal S. Sharma, Hilary J. Goldberg, Alexandra K. Wong, Alison S. Witkin, Josanna Rodriguez-Lopez, Ronald H. Goldstein, Bradley A. Maron, Bradley M. Wertheim
Format:	Article
Language:	English
Published:	Elsevier 2024-08-01
Subjects:	pulmonary arterial hypertension phosphodiesterase-type 5 inhibitor esophageal dysmotility lung transplantation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950133424000478